Literature DB >> 11390389

c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1.

J Sun1, J Zhao, M A Schwartz, J Y Wang, T Wiedmer, P J Sims.   

Abstract

Phospholipid scramblase 1 (PLSCR1) is a plasma membrane protein that has been proposed to play a role in the transbilayer movement of plasma membrane phospholipids. PLSCR1 contains multiple proline-rich motifs resembling Src homology 3 (SH3) domain-binding sites. An initial screen against 13 different SH3 domains revealed a marked specificity of PLSCR1 for binding to the Abl SH3 domain. Binding between intracellular PLSCR1 and c-Abl was demonstrated by co-immunoprecipitation of both proteins from several cell lines. Deletion of the proline-rich segment in PLSCR1 (residues 1--118) abolished its binding to the Abl SH3 domain. PLSCR1 was Tyr-phosphorylated by c-Abl in vitro. Phosphorylation was abolished by mutation of Tyr residues Tyr(69)/Tyr(74) within the tandem repeat sequence (68)VYNQPVYNQP(77) of PLSCR1, implying that these residues are the likely sites of phosphorylation. Cellular PLSCR1 was found to be constitutively Tyr-phosphorylated in several cell lines. The Tyr phosphorylation of PLSCR1 was increased upon overexpression of c-Abl and significantly reduced either upon cell treatment with the Abl kinase inhibitor STI571, or in Abl-/- mouse fibroblasts, suggesting that cellular PLSCR1 is a normal substrate of c-Abl. Cell treatment with the DNA-damaging agent cisplatin activated c-Abl kinase and increased Tyr phosphorylation of PLSCR1. The cisplatin-induced phosphorylation of PLSCR1 was inhibited by STI571 and was not observed in Abl-/- fibroblasts. These findings indicate that c-Abl binds and phosphorylates PLSCR1, and raise the possibility that an interaction between c-Abl and plasma membrane PLSCR1 might contribute to the cellular response to genotoxic stress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390389     DOI: 10.1074/jbc.M102505200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Identification of phospholipid scramblase 1 as a biomarker and determination of its prognostic value for colorectal cancer.

Authors:  Yung-Bin Kuo; Chung-Chuan Chan; C Allen Chang; Chung-Wei Fan; Ray-Ping Hung; Ya-Shu Hung; Kuei-Tien Chen; Jau-Song Yu; Yu-Sun Chang; Err-Cheng Chan
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

2.  Phospholipid scramblase 1 potentiates the antiviral activity of interferon.

Authors:  Beihua Dong; Quansheng Zhou; Ji Zhao; Aimin Zhou; Ronald N Harty; Santanu Bose; Amiya Banerjee; Roger Slee; Jeanna Guenther; Bryan R G Williams; Therese Wiedmer; Peter J Sims; Robert H Silverman
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Nuclear phospholipid scramblase 1 prolongs the mitotic expansion of granulocyte precursors during G-CSF-induced granulopoiesis.

Authors:  Chun-Wei Chen; Mark Sowden; Qian Zhao; Therese Wiedmer; Peter J Sims
Journal:  J Leukoc Biol       Date:  2011-03-29       Impact factor: 4.962

4.  MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage.

Authors:  Deepak Raina; Rehan Ahmad; Shailendra Kumar; Jian Ren; Kiyotsugu Yoshida; Surender Kharbanda; Donald Kufe
Journal:  EMBO J       Date:  2006-08-03       Impact factor: 11.598

5.  The negative c-Myc target onzin affects proliferation and apoptosis via its obligate interaction with phospholipid scramblase 1.

Authors:  Youjun Li; Kenneth Rogulski; Quansheng Zhou; Peter J Sims; Edward V Prochownik
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

6.  Phospholipid scramblase-1-induced lipid reorganization regulates compensatory endocytosis in neuroendocrine cells.

Authors:  Stéphane Ory; Mara Ceridono; Fanny Momboisse; Sébastien Houy; Sylvette Chasserot-Golaz; Dimitri Heintz; Valérie Calco; Anne-Marie Haeberlé; Flor A Espinoza; Peter J Sims; Yannick Bailly; Marie-France Bader; Stéphane Gasman
Journal:  J Neurosci       Date:  2013-02-20       Impact factor: 6.167

7.  Adiposity, dyslipidemia, and insulin resistance in mice with targeted deletion of phospholipid scramblase 3 (PLSCR3).

Authors:  Therese Wiedmer; Ji Zhao; Lilin Li; Quansheng Zhou; Andrea Hevener; Jerrold M Olefsky; Linda K Curtiss; Peter J Sims
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-24       Impact factor: 11.205

8.  N-terminal proline-rich domain is required for scrambling activity of human phospholipid scramblases.

Authors:  Sarika Rayala; Vincent G Francis; Ulaganathan Sivagnanam; Sathyanarayana N Gummadi
Journal:  J Biol Chem       Date:  2014-03-19       Impact factor: 5.157

9.  Blockade of phospholipid scramblase 1 with its N-terminal domain antibody reduces tumorigenesis of colorectal carcinomas in vitro and in vivo.

Authors:  Chung-Wei Fan; Chun-Yu Chen; Kuei-Tien Chen; Chia-Rui Shen; Yung-Bin Kuo; Ya-Shan Chen; Yeh-Pin Chou; Wei-Shan Wei; Err-Cheng Chan
Journal:  J Transl Med       Date:  2012-12-24       Impact factor: 5.531

10.  The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane.

Authors:  Bénédicte Py; Stéphane Basmaciogullari; Jérôme Bouchet; Marion Zarka; Ivan C Moura; Marc Benhamou; Renato C Monteiro; Hakim Hocini; Ricardo Madrid; Serge Benichou
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.